Logo image of CRBP

CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Fundamental Analysis

NASDAQ:CRBP - Nasdaq - US21833P3010 - Common Stock - Currency: USD

8.18  -0.1 (-1.21%)

After market: 8.33 +0.15 (+1.83%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CRBP. CRBP was compared to 572 industry peers in the Biotechnology industry. CRBP has a bad profitability rating. Also its financial health evaluation is rather negative. CRBP does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRBP had negative earnings in the past year.
CRBP had a negative operating cash flow in the past year.
In the past 5 years CRBP always reported negative net income.
In the past 5 years CRBP always reported negative operating cash flow.
CRBP Yearly Net Income VS EBIT VS OCF VS FCFCRBP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CRBP (-26.84%) is better than 72.29% of its industry peers.
The Return On Equity of CRBP (-34.81%) is better than 75.31% of its industry peers.
Industry RankSector Rank
ROA -26.84%
ROE -34.81%
ROIC N/A
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRBP Yearly ROA, ROE, ROICCRBP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K

1.3 Margins

CRBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBP Yearly Profit, Operating, Gross MarginsCRBP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

CRBP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRBP has more shares outstanding
CRBP has a worse debt/assets ratio than last year.
CRBP Yearly Shares OutstandingCRBP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
CRBP Yearly Total Debt VS Total AssetsCRBP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -2.93, we must say that CRBP is in the distress zone and has some risk of bankruptcy.
CRBP's Altman-Z score of -2.93 is in line compared to the rest of the industry. CRBP outperforms 47.42% of its industry peers.
CRBP has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CRBP (0.13) is worse than 68.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -2.93
ROIC/WACCN/A
WACCN/A
CRBP Yearly LT Debt VS Equity VS FCFCRBP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M -100M

2.3 Liquidity

A Current Ratio of 4.69 indicates that CRBP has no problem at all paying its short term obligations.
The Current ratio of CRBP (4.69) is comparable to the rest of the industry.
A Quick Ratio of 4.69 indicates that CRBP has no problem at all paying its short term obligations.
CRBP has a Quick ratio (4.69) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.69
Quick Ratio 4.69
CRBP Yearly Current Assets VS Current LiabilitesCRBP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

CRBP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.17%, which is quite impressive.
EPS 1Y (TTM)57.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.94% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.65%
EPS Next 2Y19.35%
EPS Next 3Y12.89%
EPS Next 5Y4.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRBP Yearly Revenue VS EstimatesCRBP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CRBP Yearly EPS VS EstimatesCRBP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRBP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRBP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBP Price Earnings VS Forward Price EarningsCRBP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBP Per share dataCRBP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

CRBP's earnings are expected to grow with 12.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.35%
EPS Next 3Y12.89%

More info and screens

0

5. Dividend

5.1 Amount

CRBP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (2/21/2025, 8:10:49 PM)

After market: 8.33 +0.15 (+1.83%)

8.18

-0.1 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)03-10 2025-03-10/amc
Inst Owners90.43%
Inst Owner Change-99.08%
Ins Owners1.72%
Ins Owner Change1.66%
Market Cap99.63M
Analysts85.33
Price Target57.91 (607.95%)
Short Float %21.01%
Short Ratio8.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.08%
Min EPS beat(2)24.81%
Max EPS beat(2)25.35%
EPS beat(4)4
Avg EPS beat(4)21.94%
Min EPS beat(4)2.44%
Max EPS beat(4)35.17%
EPS beat(8)4
Avg EPS beat(8)-5.03%
EPS beat(12)7
Avg EPS beat(12)4.67%
EPS beat(16)10
Avg EPS beat(16)6%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.88%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.14%
EPS NY rev (3m)-13.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.03
EV/EBITDA N/A
EPS(TTM)-4.69
EYN/A
EPS(NY)-5.84
Fwd EYN/A
FCF(TTM)-2.38
FCFYN/A
OCF(TTM)-2.38
OCFYN/A
SpS0
BVpS7.96
TBVpS7.96
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.84%
ROE -34.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-88.01%
ROA(5y)-103.66%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.69
Quick Ratio 4.69
Altman-Z -2.93
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.11%
Cap/Depr(5y)83.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.9%
EPS Next Y57.65%
EPS Next 2Y19.35%
EPS Next 3Y12.89%
EPS Next 5Y4.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5Y-15.19%
FCF growth 1Y21.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.71%
OCF growth 3YN/A
OCF growth 5YN/A